A Phase II, Single-arm Study of Combination Pembrolizumab and Olaparib in the Treatment of Patients With Advanced Cholangiocarcinoma
Latest Information Update: 24 Feb 2025
At a glance
- Drugs Olaparib (Primary) ; Pembrolizumab (Primary)
- Indications Cholangiocarcinoma; Gallbladder cancer; Liver cancer
- Focus Therapeutic Use
Most Recent Events
- 17 Feb 2025 Status changed from active, no longer recruiting to completed.
- 17 Dec 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2024.
- 06 Jun 2023 Primary endpoint (efficacy in terms of response rate) has not been met, according to a Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.